Press releases

Oncopeptides Initiates Phase II Clinical Study with Melflufen in the Treatment of Multiple Myeloma Patients.

August 20, 2013 - Other press release

Stockholm, Sweden August 20, 2013 – Oncopeptides AB, a company working to enhance oncology therapies, today announced that the first patient has been dosed as part of a Phase II study in multiple myeloma p...

Oncopeptides Secures Venture Funding for Phase II Trial of Melflufen in Multiple Myeloma Patients

May 21, 2013 - Other press release

Oncopeptides today announced the conclusion of a series A financing round intended to fund the phase II program. HealthCap led the investment with support from the long-term investor Industrifonden; members...

Welcome to Oncopeptides AB’s (publ) website. In order to optimize your use of our website we use cookies. A cookie is a text file stored on your computer. If you want more information about what a cookie is, what the purpose of the cookie is and how you can block or delete cookies, please read the our cookie guidelines “About cookies”. By continuing, you agree to our use of cookies.

Change region

Change language

Oncopeptides Initiates Phase II Clinical Study with Melflufen in the Treatment of Multiple Myeloma Patients.

Oncopeptides Secures Venture Funding for Phase II Trial of Melflufen in Multiple Myeloma Patients

Oncopeptides Initiates Phase II Clinical Study with Melflufen in the Treatment of Multiple Myeloma Patients.

Oncopeptides Secures Venture Funding for Phase II Trial of Melflufen in Multiple Myeloma Patients

Global